Assessment of immunohistochemical expression of SEMA5A as a molecular marker in endometrial cancer.
Semaphorin 5A (SEMA5A) functions not only in the nervous system but also in cancer transformation. The aim of the study was to determine the changes in SEMA5A expression in endometrial cancer compared to normal endometrium and to indicate the potential use of SEMA5A as a molecular marker. The study group consisted of 45 patients with endometrial cancer at various grades: G1, 17; G2, 15; G3, 13. The control consisted of 15 women without neoplastic changes in routine gynecological examination. The immunohistochemical assessment of SEMA5A level was performed as recommended by the manufacturer. The statistical analysis was carried out using the Statistica 12 program (p&amp;lt;0.05) based on the Kruskal-Wallis test and multiple comparisons of mean ranks. The expression of SEMA5 was observed in the control group (Me = 103.43%) and in the study group (G1, Me = 140.72%; G2, Me = 150.88%; G3, Me = 173.77%). Differences in expression between each grade and control and between individual grades turned out to be statistically significant. With the decreasing degree of endometrial cancer differentiation, the observed level of SEMA5A expression increased. Modern diagnostics and therapy are based on molecular markers. The processes occurring during carcinogenesis are associated with a change in the profile of a series of molecules. SEMA5A appears to meet the criteria for a new complementary molecular marker of endometrial cancer. Moreover, this protein also seems to be a promising target of the therapeutic strategy in this gynecological cancer.